Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

Jan Craig Buckner, Bahram Forouzesh, Charles Erlichman, Manuel Hidalgo, Joseph P. Boni, Gary Dukart, Anna Berkenblit, Eric K. Rowinsky

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

An oral formulation of temsirolimus (Torisel®), an inhibitor of the mammalian target of rapamycin, was evaluated on an intermittent schedule (once daily for 5 days every 2 weeks) in patients with advanced cancer. The maximum tolerated dose was determined to be 75 mg after dose-limiting toxicities of grade 3 elevated aminotransferases (1 patient) and grade 3 rash (1 patient) occurred with a 100-mg dose. The most common temsirolimus-related adverse events were mucositis, rash/maculopapular rash, and asthenia. Six of 12 patients who received the 75-mg dose required dose reductions due to temsirolimus-related adverse events. Two patients who received 75-mg temsirolimus and did not have dose reductions had minor tumor responses. Relative exposure from contributions of both temsirolimus and sirolimus, the principal metabolite, was 17.9% of the 75-mg dose. Thus, oral temsirolimus, 75 mg administered once daily for 5 days every 2 weeks, was further evaluated in patients with metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)334-342
Number of pages9
JournalInvestigational New Drugs
Volume28
Issue number3
DOIs
StatePublished - Jun 2010

Fingerprint

Pharmacokinetics
Exanthema
Neoplasms
Sirolimus
Asthenia
Mucositis
Maximum Tolerated Dose
Transaminases
temsirolimus
Appointments and Schedules
Breast Neoplasms

Keywords

  • MTOR
  • Pharmacokinetics
  • Phase I
  • Targeted chemotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. / Buckner, Jan Craig; Forouzesh, Bahram; Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P.; Dukart, Gary; Berkenblit, Anna; Rowinsky, Eric K.

In: Investigational New Drugs, Vol. 28, No. 3, 06.2010, p. 334-342.

Research output: Contribution to journalArticle

Buckner, JC, Forouzesh, B, Erlichman, C, Hidalgo, M, Boni, JP, Dukart, G, Berkenblit, A & Rowinsky, EK 2010, 'Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer', Investigational New Drugs, vol. 28, no. 3, pp. 334-342. https://doi.org/10.1007/s10637-009-9257-1
Buckner, Jan Craig ; Forouzesh, Bahram ; Erlichman, Charles ; Hidalgo, Manuel ; Boni, Joseph P. ; Dukart, Gary ; Berkenblit, Anna ; Rowinsky, Eric K. / Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. In: Investigational New Drugs. 2010 ; Vol. 28, No. 3. pp. 334-342.
@article{4fab300bbf29473c910f16784665814e,
title = "Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer",
abstract = "An oral formulation of temsirolimus (Torisel{\circledR}), an inhibitor of the mammalian target of rapamycin, was evaluated on an intermittent schedule (once daily for 5 days every 2 weeks) in patients with advanced cancer. The maximum tolerated dose was determined to be 75 mg after dose-limiting toxicities of grade 3 elevated aminotransferases (1 patient) and grade 3 rash (1 patient) occurred with a 100-mg dose. The most common temsirolimus-related adverse events were mucositis, rash/maculopapular rash, and asthenia. Six of 12 patients who received the 75-mg dose required dose reductions due to temsirolimus-related adverse events. Two patients who received 75-mg temsirolimus and did not have dose reductions had minor tumor responses. Relative exposure from contributions of both temsirolimus and sirolimus, the principal metabolite, was 17.9{\%} of the 75-mg dose. Thus, oral temsirolimus, 75 mg administered once daily for 5 days every 2 weeks, was further evaluated in patients with metastatic breast cancer.",
keywords = "MTOR, Pharmacokinetics, Phase I, Targeted chemotherapy",
author = "Buckner, {Jan Craig} and Bahram Forouzesh and Charles Erlichman and Manuel Hidalgo and Boni, {Joseph P.} and Gary Dukart and Anna Berkenblit and Rowinsky, {Eric K.}",
year = "2010",
month = "6",
doi = "10.1007/s10637-009-9257-1",
language = "English (US)",
volume = "28",
pages = "334--342",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

AU - Buckner, Jan Craig

AU - Forouzesh, Bahram

AU - Erlichman, Charles

AU - Hidalgo, Manuel

AU - Boni, Joseph P.

AU - Dukart, Gary

AU - Berkenblit, Anna

AU - Rowinsky, Eric K.

PY - 2010/6

Y1 - 2010/6

N2 - An oral formulation of temsirolimus (Torisel®), an inhibitor of the mammalian target of rapamycin, was evaluated on an intermittent schedule (once daily for 5 days every 2 weeks) in patients with advanced cancer. The maximum tolerated dose was determined to be 75 mg after dose-limiting toxicities of grade 3 elevated aminotransferases (1 patient) and grade 3 rash (1 patient) occurred with a 100-mg dose. The most common temsirolimus-related adverse events were mucositis, rash/maculopapular rash, and asthenia. Six of 12 patients who received the 75-mg dose required dose reductions due to temsirolimus-related adverse events. Two patients who received 75-mg temsirolimus and did not have dose reductions had minor tumor responses. Relative exposure from contributions of both temsirolimus and sirolimus, the principal metabolite, was 17.9% of the 75-mg dose. Thus, oral temsirolimus, 75 mg administered once daily for 5 days every 2 weeks, was further evaluated in patients with metastatic breast cancer.

AB - An oral formulation of temsirolimus (Torisel®), an inhibitor of the mammalian target of rapamycin, was evaluated on an intermittent schedule (once daily for 5 days every 2 weeks) in patients with advanced cancer. The maximum tolerated dose was determined to be 75 mg after dose-limiting toxicities of grade 3 elevated aminotransferases (1 patient) and grade 3 rash (1 patient) occurred with a 100-mg dose. The most common temsirolimus-related adverse events were mucositis, rash/maculopapular rash, and asthenia. Six of 12 patients who received the 75-mg dose required dose reductions due to temsirolimus-related adverse events. Two patients who received 75-mg temsirolimus and did not have dose reductions had minor tumor responses. Relative exposure from contributions of both temsirolimus and sirolimus, the principal metabolite, was 17.9% of the 75-mg dose. Thus, oral temsirolimus, 75 mg administered once daily for 5 days every 2 weeks, was further evaluated in patients with metastatic breast cancer.

KW - MTOR

KW - Pharmacokinetics

KW - Phase I

KW - Targeted chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=77952236657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952236657&partnerID=8YFLogxK

U2 - 10.1007/s10637-009-9257-1

DO - 10.1007/s10637-009-9257-1

M3 - Article

VL - 28

SP - 334

EP - 342

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -